3rd Fluid & Imaging Biomarkers in Neuroscience Summit

With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, and α-syn self-seeding assay sensitivity and enhancing NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation. The 2nd Fluid & Imaging Biomarkers & Endpoints in Neuroscience forum united biomarker discovery scientists, imaging experts, neuroscience clinical program leads, and regulatory leaders to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics. October 2024, joined 50+ biomarker discovery scientists, imaging experts, neuroscience clinical program leaders, and regulatory leaders from renowned organizations like Alector, Biogen, Bristol Myers Squibb, Eli Lilly, Eisai, Pfizer, Takeda, Regeneron, and the Michael J. Fox Foundation and many more at the ultimate unique industry-focused networking opportunity to advance precision medicine in neurodegenerative and neuroinflammatory diseases.